Immunomodulatory effect of naloxone in duodenal ulcer patients.

[1]  T. Strom,et al.  Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. , 1986, Journal of immunology.

[2]  R. Suzuki,et al.  Production of a cytokine with interleukin 3-like properties and cytokine-dependent proliferation in human autologous mixed lymphocyte reaction , 1986, The Journal of experimental medicine.

[3]  T. Wong,et al.  NALOXONE ATTENUATES AUGMENTATION OF cAMP LEVELS AND ARRHYTHMIAS FOLLOWING MYOCARDIAL ISCHAEMIA AND REPERFUSION IN THE ISOLATED PERFUSED RAT HEART , 1986, Clinical and experimental pharmacology & physiology.

[4]  L. Cubeddu,et al.  Cardiovascular and endocrine effects of naloxone compared in normotensive and hypertensive patients. , 1986, European journal of pharmacology.

[5]  M. Johnson,et al.  Naloxone inhibits superoxide release from human neutrophils. , 1985, Life sciences.

[6]  E. M. Smith,et al.  Lymphocyte production of endorphins and endorphin-mediated immunoregulatory activity. , 1985, Journal of immunology.

[7]  E. Levin,et al.  Studies of naloxone-induced secretion of β-endorphin immunoreactivity in dogs , 1984 .

[8]  R. Maca.  The effects of cyclic nucleotides on the proliferation of cultured human T-lymphocytes. , 1984, Immunopharmacology.

[9]  J. Morley,et al.  Endorphins stimulate normal human peripheral blood lymphocyte natural killer activity. , 1984, Life sciences.

[10]  D. Klatzmann,et al.  The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. , 1984, Journal of immunology.

[11]  S. Gupta,et al.  Autologous Mixed Lymphocyte Reaction in Health and Disease States in Man , 1983, Vox sanguinis.

[12]  A. Murgo,et al.  Enkephalins--enhancement of active T-cell rosettes from lymphoma patients. , 1983, Clinical immunology and immunopathology.

[13]  R. Herberman,et al.  Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. , 1983, Journal of immunology.

[14]  F. Bloom,et al.  beta-Endorphin enhances lymphocyte proliferative responses. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. M. Smith,et al.  Regulation of the in vitro antibody response by neuroendocrine hormones. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Flamm,et al.  Lipid antioxidant properties of naloxone in vitro. , 1981, Biochemical and biophysical research communications.

[17]  C. Pinsky,et al.  On the specificity of naloxone as an opiate antagonist. , 1979, Life sciences.

[18]  P. Cuatrecasas,et al.  Specific nonopiate receptors for beta-endorphin. , 1979, Science.

[19]  Kendall A. Smith,et al.  T cell growth factor: parameters of production and a quantitative microassay for activity. , 1978, Journal of immunology.

[20]  Elizabeth Simpson,et al.  A rapid method for the isolation of functional thymus‐derived murine lymphocytes , 1973, European journal of immunology.

[21]  K. Markiewicz,et al.  Changes in the interleukin-1 and interleukin-2 generation in duodenal ulcer patients during cimetidine treatment. , 1985, Immunology letters.

[22]  J. Wybran.  Enkephalins and endorphins as modifiers of the immune system: present and future. , 1985, Federation proceedings.

[23]  R. Faith,et al.  Effects of opiates and neuropeptides on immune functions. , 1984, NIDA research monograph.

[24]  G. Solomon,et al.  Psychoneuroendocrinological effects on the immune response. , 1981, Annual review of microbiology.

[25]  L L Iversen,et al.  Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. , 1978, European journal of pharmacology.